You are here: Home » News-IANS » Health-Medicine
Business Standard

'Need to increase pace of research in regenerative medicine'

IANS  |  Mumbai 

needs to increase the pace of research in regenerative medicine to come up to the global level, especially in the area of clinical trials and regulatory requirements, a doctor said on Saturday.

"Autologous cell therapies with minimum manipulation also need standardisation. A national level consortium should be formed consisting of governing authorities, academia, industry partners, researchers with the common goal of making mesenchymal stem cells available as Living Drugs to masses," said Pradeep Mahajan, Founder Chairman of StemRx, an organisation in the field of regenerative medicine and cell based therapy.

He was speaking at the International Conference on Regenerative Medicine and Stem Cells.

Mahajan was invited to share his knowledge on Mesenchymal Stem Cells- the new drug on the horizon. During the conference he emphasised on how a single cell when applied properly can work as a multi-action drug.

According to Mahajan, one of the reasons is unable to research more on regenerative medicine is the health burden due to chronic debilitating diseases like diabetes, heart problems, neurodegenerative disorders like Parkinson's and financial burden caused by it.

"With advent of cell based therapy and their availability such disease conditions can reduce these burdens to a great extent," said Mahajan.

--IANS

rup/pgh/bg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

'Need to increase pace of research in regenerative medicine'

India needs to increase the pace of research in regenerative medicine to come up to the global level, especially in the area of clinical trials and regulatory requirements, a doctor said on Saturday.

needs to increase the pace of research in regenerative medicine to come up to the global level, especially in the area of clinical trials and regulatory requirements, a doctor said on Saturday.

"Autologous cell therapies with minimum manipulation also need standardisation. A national level consortium should be formed consisting of governing authorities, academia, industry partners, researchers with the common goal of making mesenchymal stem cells available as Living Drugs to masses," said Pradeep Mahajan, Founder Chairman of StemRx, an organisation in the field of regenerative medicine and cell based therapy.

He was speaking at the International Conference on Regenerative Medicine and Stem Cells.

Mahajan was invited to share his knowledge on Mesenchymal Stem Cells- the new drug on the horizon. During the conference he emphasised on how a single cell when applied properly can work as a multi-action drug.

According to Mahajan, one of the reasons is unable to research more on regenerative medicine is the health burden due to chronic debilitating diseases like diabetes, heart problems, neurodegenerative disorders like Parkinson's and financial burden caused by it.

"With advent of cell based therapy and their availability such disease conditions can reduce these burdens to a great extent," said Mahajan.

--IANS

rup/pgh/bg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

'Need to increase pace of research in regenerative medicine'

needs to increase the pace of research in regenerative medicine to come up to the global level, especially in the area of clinical trials and regulatory requirements, a doctor said on Saturday.

"Autologous cell therapies with minimum manipulation also need standardisation. A national level consortium should be formed consisting of governing authorities, academia, industry partners, researchers with the common goal of making mesenchymal stem cells available as Living Drugs to masses," said Pradeep Mahajan, Founder Chairman of StemRx, an organisation in the field of regenerative medicine and cell based therapy.

He was speaking at the International Conference on Regenerative Medicine and Stem Cells.

Mahajan was invited to share his knowledge on Mesenchymal Stem Cells- the new drug on the horizon. During the conference he emphasised on how a single cell when applied properly can work as a multi-action drug.

According to Mahajan, one of the reasons is unable to research more on regenerative medicine is the health burden due to chronic debilitating diseases like diabetes, heart problems, neurodegenerative disorders like Parkinson's and financial burden caused by it.

"With advent of cell based therapy and their availability such disease conditions can reduce these burdens to a great extent," said Mahajan.

--IANS

rup/pgh/bg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard